|
|
Apyx Medical Corporation (APYX) |
|
Price: $1.2200
$-0.05 
-3.937%
|
| Day's High:
| $1.25
| Week Perf:
| 2.22 %
|
| Day's Low: |
$ 1.20 |
30 Day Perf: |
-2.4 % |
| Volume (M): |
4 |
52 Wk High: |
$ 3.32 |
| Volume (M$): |
$ 5 |
52 Wk Avg: |
$1.77 |
| Open: |
$1.25 |
52 Wk Low: |
$0.97 |
|
|
| Market Capitalization (Millions $) |
42 |
| Shares
Outstanding (Millions) |
35 |
| Employees |
38 |
| Revenues (TTM) (Millions $) |
48 |
| Net Income (TTM) (Millions $) |
-28 |
| Cash Flow (TTM) (Millions $) |
14 |
| Capital Exp. (TTM) (Millions $) |
1 |
Apyx Medical Corporation
Apyx Medical Corporation is a leading medical technology company that specializes in developing and commercializing innovative solutions for various surgical procedures. The company is known for its flagship product called the J-Plasma system, which utilizes a unique energy system to provide controlled and precise tissue cutting, coagulation, and ablation. Apyx Medical Corporation's technology is widely used in the fields of plastic surgery, dermatology, and other surgical specialties. The company aims to improve patient outcomes and enhance surgical precision by continuously innovating and developing advanced medical devices.
Company Address: 5115 Ulmerton Road, Clearwater 33760 FL
Company Phone Number: 384-2323 Stock Exchange / Ticker: NASDAQ APYX
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Fri, Aug 9 2024 5:10 AM UTC
In the rapidly evolving field of cosmetic surgery, where advancements in technology can define operational success and patient outcomes, Apyx Medical Corporation has made a significant leap forward. The company recently announced the publication of a peer-reviewed clinical study, featured in the journal Plastic and Reconstructive Surgery Global Open, which compares its propr...
|
| Business Update
Published Thu, Aug 8 2024 8:47 PM UTC
''Apyx Medical Corporation, a Clearwater, Florida-based company specializing in innovative medical technologies, has recently announced a significant milestone in its research efforts. The company revealed the publication of a peer-reviewed article in the journal 'Plastic and Reconstructive Surgery - Global Open'. This article details a clinical study that compared the effec...
|
| Apyx Medical Corporation
Apyx Medical Corporation, a leading manufacturer of proprietary helium plasma and radiofrequency technology, recently announced its financial results for the first quarter of fiscal year 2024. The company's preliminary revenue results for the fourth quarter and full year ended December 31, 2023, demonstrated remarkable growth, reflecting its continued success in the medical technology sector.
In the fourth quarter of 2023, Apyx Medical Corporation achieved total revenues between approximately $14.2 to $14.6 million, which marked an impressive year-over-year growth of 13% to 16%. This significant increase is a testament to the company's exceptional performance and solid market demand for its innovative products and services. Additionally, the revenue generated from Advanced Energy solutions witnessed notable growth during this period.
|
| Apyx Medical Corporation
Apyx Medical Corporation, a leading manufacturer of medical technology known as Renuvion, recently announced its financial results for the fourth quarter and full year ended December 31, 2023. The company recorded impressive growth in both periods, demonstrating its success in the medical technology sector.
In the fourth quarter of 2023, Apyx Medical Corporation achieved total revenues between approximately $14.2 to $14.6 million, marking a year-over-year increase of 13% to 16%. This substantial growth reflects the company's strong performance and solid market demand for its innovative products and services. Notably, the revenue generated from Advanced Energy solutions witnessed remarkable growth during the period.
|
| Contract
Published Mon, Jan 8 2024 12:00 PM UTC
CLEARWATER, Fla. - Apyx Medical Corporation (NASDAQ: APYX), a leading manufacturer of proprietary helium plasma and radiofrequency technology known as Renuvion, has recently announced its preliminary revenue results for the fourth quarter and full year ended December 31, 2023. The company recorded remarkable growth in both periods, demonstrating its continued success in the ...
|
| Per Share |
Current |
| Earnings (TTM) |
-0.8 $ |
| Revenues (TTM) |
1.38 $
|
| Cash Flow (TTM) |
0.41 $ |
| Cash |
0.95 $
|
| Book Value |
0.43 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.8 $
|
| Revenues (TTM) |
1.38 $ |
| Cash Flow (TTM) |
0.41 $ |
| Cash |
0.95 $
|
| Book Value |
0.43 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Advanced Energy |
|
 80.39 % |
of total Revenue |
| OEM |
|
19.61 % |
of total Revenue |
| Corporate & Other |
|
100 % |
of total Revenue |
| Domestic |
|
71.5 % |
of total Revenue |
| International |
|
28.5 % |
of total Revenue |
| |
On March 21 2024 the Apyx Medical provided following guidance
Apyx Medical Corporation, a leading provider of innovative medical technologies including its proprietary helium plasma and radiofrequency technology under the brand name Renuvion, announced its financial results for the fourth quarter and full year of 2023. The Company reported a total revenue of $14.7 million, marking a 16% increase compared to the previous year.
Furthermore, Apyx Medical introduced its financial outlook for the full year ending December 31, 2024. The Company is optimistic about its growth prospects and is forecasting strong performance in the upcoming year. With a track record of success and a commitment to innovation, Apyx Medical is well-positioned to continue its upward trajecto...
|
|
|
